Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera

Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Ranawaka A. P. M., Ko, Ronald, Tsang, Owen T. Y., Hui, David S. C., Kwan, Mike Y. M., Brackman, Christopher J., To, Esther M. W., Yen, Hui-ling, Leung, Kathy, Cheng, Samuel M. S., Chan, Kin Ho, Chan, Karl C. K., Li, Ka-Chi, Saif, Linda, Barrs, Vanessa R., Wu, Joseph T., Sit, Thomas H. C., Poon, Leo L. M., Peiris, Malik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Immunoassays
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111130/
https://www.ncbi.nlm.nih.gov/pubmed/33139421
http://dx.doi.org/10.1128/JCM.02504-20
Descripción
Sumario:Surrogate neutralization assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be done without biosafety level 3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT(90)) in human, canine, cat, and hamster sera. With PRNT(90) as the reference, sVNT had sensitivity of 98.9% and specificity of 98.8%. Using a panel of immune sera corresponding to other coronaviruses, we confirm the lack of cross-reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT(90), except for cross-reactivity to SARS-CoV-1 in sVNT.

Ejemplares similares